Abstract
Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progressed (40%). Toxicity was acceptable, consisting mainly of myalgias (39% of patients) and asthenia (21.4%). No myelotoxicity was observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern of action and toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bagnato A., Bianchi C., Caputo A., Silvestrini B., Floridi A. Enhancing effect of lonidamine on the inhibition of mitochondrial respiration by adriamycin. Anticancer Res. 1987 Jul-Aug;7(4B):799–802. [PubMed] [Google Scholar]
- Band P. R., Maroun J., Pritchard K., Stewart D., Coppin C. M., Wilson K., Eisenhauer E. A. Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep. 1986 Nov;70(11):1305–1310. [PubMed] [Google Scholar]
- Chitnis M., Adwankar M. Potentiation of adriamycin cytotoxicity in P388 murine leukemia sensitive and resistant to adriamycin by use of lonidamine and hyperthermia. Tumori. 1986 Oct 31;72(5):469–473. doi: 10.1177/030089168607200503. [DOI] [PubMed] [Google Scholar]
- Giannotti P., Ambrogi F., Ciottoli G. B. Lonidamine plus adriamycin versus adriamycin alone in the adjuvant treatment of recurrent papillary carcinomas of the urinary bladder. Oncology. 1984;41 (Suppl 1):104–107. doi: 10.1159/000225896. [DOI] [PubMed] [Google Scholar]
- Hahn G. M., van Kersen I., Silvestrini B. Inhibition of the recovery from potentially lethal damage by lonidamine. Br J Cancer. 1984 Nov;50(5):657–660. doi: 10.1038/bjc.1984.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Magno L., Terraneo F., Ciottoli G. B. Lonidamine and radiotherapy in head and neck cancers. A pilot study. Oncology. 1984;41 (Suppl 1):113–115. doi: 10.1159/000225898. [DOI] [PubMed] [Google Scholar]
- Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
- Pacilio G., Carteni G., Biglietto M., De Cesare M. Lonidamine alone and in combination with other chemotherapeutic agents in the treatment of cancer patients. Oncology. 1984;41 (Suppl 1):108–112. doi: 10.1159/000225897. [DOI] [PubMed] [Google Scholar]
- Silvestrini B., Hahn G. M., Cioli V., De Martino C. Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems. Br J Cancer. 1983 Feb;47(2):221–231. doi: 10.1038/bjc.1983.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weinerman B. H., Eisenhauer E. A., Besner J. G., Coppin C. M., Stewart D., Band P. R. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep. 1986 Jun;70(6):751–754. [PubMed] [Google Scholar]
- Zupi G., Greco C., Laudonio N., Benassi M., Silvestrini B., Caputo A. In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. Anticancer Res. 1986 Sep-Oct;6(5):1245–1249. [PubMed] [Google Scholar]